Onyx Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition by Amgen

 August 26, 2013

Bernstein Liebhard LLP is investigating whether the Board of Directors of Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”) (NASDAQ: ONXX) breached its fiduciary duty to its shareholders in agreeing to sell Onyx to Amgen.

Under the terms of the agreement, Onyx shareholders will receive $125.00 in cash for each share they own.  The investigation is focused on the potential unfairness of the price to Onyx shareholders and the process by which the Onyx Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as an Onyx stockholder, with no obligation or cost to you, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients.  It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last ten years.